LEIDEN, The Netherlands, January 16 /PRNewswire/ -- OctoPlus, the drug
delivery and development company, today announced two new appointments to its
senior management team.
Mr. Gerben Moolhuizen, MBA, previously Director OctoPlus Products, is
promoted to Chief Business Officer and will join the company's senior
management team. He replaces Dr. Henrik Luessen who is leaving to start his
own consulting company, after seven years at OctoPlus.
Gerben Moolhuizen joined the company in December 2001. Prior to joining
OctoPlus he held business development positions at Primagen, Pharming and
Eurocetus (now Chiron) where he gained more than 14 years of experience in
successful deal making and obtaining venture capital financing for life
science companies. Mr. Moolhuizen received his MBA from the Rotterdam School
of Management and his M.Sc. in Medical Biology from Utrecht University.
In addition, OctoPlus has recruited Dr. Ewoud van Hoogdalem to become
Chief Medical Officer and a member of the management team. Ewoud van
Hoogdalem was previously Director Experimental Medicine with Johnson &
Johnson Pharmaceutical R&D based in Belgium. He brings to OctoPlus more than
16 years of experience from Gist-Brocades (now DSM), Yamanouchi Europe and
Johnson & Johnson, in clinical development from preclinical up to late
clinical phases. Dr. Van Hoogdalem received his Ph.D. in Pharmacology and his
M.Sc. in Pharmacy from Leiden University, and is a registered Clinical
'We are pleased to welcome both Gerben and Ewoud to our senior team at
this key time in OctoPlus' development' comments Dr. Joost Holthuis, CEO of
OctoPlus. 'At the same time, we want to thank Dr. Luessen for his significant
contributions and wish him every success with his own company.'
About OctoPlus OctoPlus is a product-oriented drug delivery company that
focuses on the development of innovative drug delivery systems to build a
pipeline of product candidates. OctoPlus is also an internationally
established provider of pharmaceutical development services and GMP
manufacturing for pharmaceutical and biotechnology companies. The company is
located in Leiden, the Netherlands.
OctoPlus was founded in 1995 and currently employs more than 120 people.
In January 2005 the company raised EUR 18 million in a second financing round
from an international group of investors: Life Sciences Partners II B.V.
(Amsterdam, the Netherlands), S.R. One, Ltd. (West Conshohocken, PA, USA),
Innoven Partenaires (Paris, France), Fortis Private Equity (Brussels,
Belgium) and SurModics, Inc. (Minneapolis, MN, USA).